AnodyneWiki

Nevirapine

Nevirapine
Nevirapine
Salts
[]
Nevirapine hemihydrate
Nevirapine hemihydrate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass266.30 g/mol [1]
AppearanceCrystals from pyridine and water [1]
Melting point196.06 [1]
Solubility0.7046 mg/L [1]
Predicted LogP2 [1]
Structural Identifiers
[]
Molecular formulaC15H14N4O
IUPAC name2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
SMILESCC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
InChIInChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
InChIKeyNQDJXKOVJZTUJA-UHFFFAOYSA-N
CAS number129618-40-2
UNII99DK7FVK1H
PubChem CID4463
Pharmacokinetics[]
Elimination half-life45 hours
MetabolismLiver
ExcretionKidney: <6% (Parent drug) , Bile duct <5% (Parent drug)
Routes of administrationBy mouth

Nevirapine (also known as Viramune, Bi-rg-587, Nevirapine anhydrous, Viramune XR, Birg 0587, Nevirapine teva, Nevirapina, Nevirapine, anhydrous, Birg587 or Birg-0587).

Chemistry

Salts []

Nevirapine is typically found in the form of its hemihydrate salt.

 []

Nevirapine is achiral.

Nevirapine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

metabolism / inhibition / induction779 (4 contraindicated)
metabolism / inhibition / induction193
metabolism / induction / inhibition58

Medical side effects []

110 side effects listed on drug labels in (nevirapine).

  • Dermatitis
  • Rash
  • Liver function test abnormal
  • Alanine aminotransferase increased
  • Headache
  • Abdominal pain
  • Gastrointestinal pain
  • Diarrhoea
  • Nausea
  • Hepatotoxicity
  • Myalgia
  • Musculoskeletal discomfort
  • Arthralgia
  • Drug eruption
  • Blood pressure increased
  • Blood phosphorus decreased
  • Agranulocytosis
  • Asthenia
  • Fatigue
  • Toxic epidermal necrolysis
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Anaphylactic shock
  • Anaemia
  • Angioedema
  • Blister
  • Dermatitis bullous
  • Bullous eruption
  • Conjunctivitis
  • Oedema
  • Eosinophilia
  • Body temperature increased
  • Hepatitis
  • Hypersensitivity
  • Jaundice
  • Neutropenia
  • Paraesthesia
  • Paraesthesia skin
  • Rhabdomyolysis
  • Mouth ulceration
  • Urticaria
  • Vomiting
  • Hepatic failure
  • Oral disorder
  • Hepatitis cholestatic
  • Hepatic necrosis
  • Malaise
  • Discomfort
  • Feeling abnormal
  • Ill-defined disorder
  • Pain
  • Hepatitis fulminant
  • Lymphadenopathy
  • Face oedema
  • Drug reaction with eosinophilia and systemic symptoms
  • Drug interaction
  • Somnolence
  • Congenital anomaly
  • Developmental delay
  • Decreased appetite
  • Autoimmune disorder
  • Bone disorder
  • Connective tissue disorder
  • Dermatitis exfoliative
  • Erythema nodosum
  • Gastrointestinal disorder
  • Basedow's disease
  • Hepatitis toxic
  • Hypercholesterolaemia
  • Hyperglycaemia
  • Hypertriglyceridaemia
  • Blood triglycerides increased
  • Breast enlargement
  • Immune system disorder
  • Inflammation
  • Insulin resistance
  • Lipodystrophy acquired
  • Liver disorder
  • Hepatocellular injury
  • Foetor hepaticus
  • Necrosis
  • Nervous system disorder
  • Opportunistic infection
  • Pancreatitis
  • Neuropathy peripheral
  • Pruritus
  • Renal failure
  • Thrombocytopenia
  • Ulcer
  • Erythema
  • Gamma-glutamyltransferase increased
  • Aspartate aminotransferase increased
  • Liver injury
  • Traumatic liver injury
  • Skin disorder
  • Rash erythematous
  • Hepatic enzyme increased
  • Skin exfoliation
  • Vertical infection transmission
  • Hepatobiliary disease
  • Hepatitis acute
  • Rash maculo-papular
  • Transaminases increased
  • Lipohypertrophy
  • Chronic hepatitis B
  • Surgery
  • Hyperlactacidaemia
  • Fat redistribution
  • Rash papular
  • Hypertransaminasaemia

Indications

  • Acquired immunodeficiency syndrome
  • Hepatotoxicity
  • Infection
  • Rash

 []

  • Australia: Nevirapine is a Schedule 4.[3]
  • United States: Nevirapine is Prescription only.
  • European Union: Nevirapine is Prescription only.

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 4463, Nevirapine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4463
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Nevirapine. UNII: 99DK7FVK1H. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/99DK7FVK1H
  3. Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 21 June 2022. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 18:01:18
drugspromissing (no DrugsPRO reagent data)2026-11-20 18:01:14
erowidmissing (no Erowid substance of that name)2026-11-20 18:01:14
gsrsok2026-11-20 18:01:15
hmdbmissing (hmdb.ca refused automated access to HMDB0014383)2026-11-20 18:01:14
keggok2026-11-20 18:01:17
pubchemok2026-11-20 18:01:14
redditmissing (no r/tripreports posts mention it)2026-11-20 18:01:14
siderok2026-11-20 18:01:14
structureok2026-11-20 18:01:14
wikipediaok2026-11-20 18:01:15